Literature DB >> 9105404

Distinction of CYP1A1 and CYP1A2 activity by selective inhibition using fluvoxamine and isosafrole.

A Pastrakuljic1, B K Tang, E A Roberts, W Kalow.   

Abstract

Ethoxyresorufin O-deethylation (EROD) has been used as a specific probe for CYP1A1 and CYP1A2. Selective inhibition of one of these cytochromes P450 may differentiate their activity in human liver. Four inhibitors were chosen to examine the selective inhibition of EROD activity, using cDNA of CYP1A1 and CYP1A2. The two flavones, alpha-naphthoflavone and apigenin, while differing in potency, inhibited expressed human CYP1A1, CYP1A2, and human liver microsomes to a similar extent. Isosafrole and fluvoxamine were found to inhibit CYP1A2 selectively, with Ki values of 14 and 800 times, respectively, lower than those for CY1A1. A set of equations was developed to estimate both CYP1A1 and CYP1A2 activity. Levels of CYP1A2 in four human liver specimens ranged from 44.4 to 76.7 pmol/mg protein, which significantly correlated with phenacetin O-deethylase activity (r = 0.99; P < 0.001). Low levels of CYP1A1 activity were present in all four investigated livers, ranging from 0.4 to 2.7 pmol/mg protein.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9105404     DOI: 10.1016/s0006-2952(96)00769-1

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  12 in total

Review 1.  Spotlight on fluvoxamine in anxiety disorders in children and adolescents.

Authors:  Susan M Cheer; David P Figgitt
Journal:  CNS Drugs       Date:  2002       Impact factor: 5.749

Review 2.  Fluvoxamine. An updated review of its use in the management of adults with anxiety disorders.

Authors:  D P Figgitt; K J McClellan
Journal:  Drugs       Date:  2000-10       Impact factor: 9.546

Review 3.  Fluvoxamine: a review of its therapeutic potential in the management of anxiety disorders in children and adolescents.

Authors:  S M Cheer; D P Figgitt
Journal:  Paediatr Drugs       Date:  2001       Impact factor: 3.022

4.  The revised human liver cytochrome P450 "Pie": absolute protein quantification of CYP4F and CYP3A enzymes using targeted quantitative proteomics.

Authors:  Scott Michaels; Michael Zhuo Wang
Journal:  Drug Metab Dispos       Date:  2014-05-09       Impact factor: 3.922

5.  Neuroimmune endocrine effects of antidepressants.

Authors:  Marco Antonioli; Joanna Rybka; Livia A Carvalho
Journal:  Neuropsychiatr Dis Treat       Date:  2012-02-07       Impact factor: 2.570

6.  Mechanisms of acquired resistance to 2-(4-aminophenyl)benzothiazole (CJM 126, NSC 34445).

Authors:  T D Bradshaw; M S Chua; S Orr; C S Matthews; M F Stevens
Journal:  Br J Cancer       Date:  2000-07       Impact factor: 7.640

7.  Poly(ADP-ribosyl)ated PXR is a critical regulator of acetaminophen-induced hepatotoxicity.

Authors:  Cheng Wang; Wenjing Xu; Yanqing Zhang; Dan Huang; Kai Huang
Journal:  Cell Death Dis       Date:  2018-07-26       Impact factor: 8.469

8.  Defining the Contribution of CYP1A1 and CYP1A2 to Drug Metabolism Using Humanized CYP1A1/1A2 and Cyp1a1/Cyp1a2 Knockout Mice.

Authors:  Y Kapelyukh; C J Henderson; N Scheer; A Rode; C R Wolf
Journal:  Drug Metab Dispos       Date:  2019-05-30       Impact factor: 3.922

9.  Interaction of Thalassia testudinum Metabolites with Cytochrome P450 Enzymes and Its Effects on Benzo(a)pyrene-Induced Mutagenicity.

Authors:  Livan Delgado-Roche; Rebeca Santes-Palacios; José A Herrera; Sandra L Hernández; Mario Riera; Miguel D Fernández; Fernando Mesta; Gabino Garrido; Idania Rodeiro; Jesús Javier Espinosa-Aguirre
Journal:  Mar Drugs       Date:  2020-11-19       Impact factor: 5.118

10.  Resveratrol Downregulates Cyp2e1 and Attenuates Chemically Induced Hepatocarcinogenesis in SD Rats.

Authors:  Xiongfei Wu; Chenggang Li; Guozhen Xing; Xinming Qi; Jin Ren
Journal:  J Toxicol Pathol       Date:  2013-12-26       Impact factor: 1.628

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.